Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, …
Full CTNM analysis →
Competitive advantage assessment
Key strengths
Strong Interest Coverage & Conservative LeverageDebt serviceability is strong (score 0.73), with robust interest coverage.
Consistent Cash GenerationCash generation is strong and consistent (score 0.95).
Key risks
Revenue Volatility Signals Weak StickinessRevenue volatility is high (stability score 0.00), suggesting weak customer stickiness.
Volatile Margins Suggest CyclicalityMargin volatility is high (stability score 0.00), suggesting cyclical exposure or competitive pressure.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Contineum Therapeutics, Inc. ranks #42 of 713
scored companies in Biotechnology by moat score — the top 6%.
The widest moat in the group is Royalty Pharma plc (RPRX)
at 85/100.
Moat scores for companies ranked near CTNM in Biotechnology
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 89
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 95
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 44
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 84
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 89
· 15% of the moat score
Scale matters only when it converts into economics.
What is Contineum Therapeutics, Inc.'s moat score?
Contineum Therapeutics, Inc. (CTNM) scores 72 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #42 of 713 scored companies in Biotechnology, the top 6%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (95/100) and its weakest is Capital Efficiency (44/100).
How does Contineum Therapeutics, Inc. compare with other Biotechnology companies?
Contineum Therapeutics, Inc. ranks #42 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are MannKind Corporation (MNKD) at 72 just above it and Keros Therapeutics, Inc. (KROS) at 72 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.
Why is Contineum Therapeutics, Inc. scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Contineum Therapeutics, Inc.?
The Corporate Default template measures 6 defenses, and CTNM scores: Pricing Power (45), Cost Advantage (89), Customer Stickiness (95), Capital Efficiency (44), Resilience (84), Scale & Market Position (89). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.